Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOXM1 | Q08050 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.56 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.54 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.47 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69474 | 0.83 | BCHE (0.51) | FOXM1BCHECYP4F2CYP4A11CYP2D6 | |
| SCHEMBL12204184 | 0.82 | ALDH1A1 (0.72) | TAAR1KDM4EALDH1A1 | |
| SCHEMBL787022 | 0.81 | ALDH1A1 (0.74) | TAAR1KDM4EALDH1A1 | |
| SCHEMBL3665298 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL22216853 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL25002632 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL21792273 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24767088 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL24075499 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1240954 | 0.80 | TAAR1 (0.84) | TAAR1KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | FOXM1 4180/4885TAAR1 4711/4885KDM4E 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.